Known targets — ChEMBL curated mechanism
ABL1BCRBLKEPHA2FGRFRKFYNHCKKITLCKLYNPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Dasatinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 10/20 | 0.98 |
| ▸ | SRC known ✓ | P12931 | 5/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 0.98 |
| ▸ | FYN known ✓ | P06241 | 2/20 | 0.98 |
| ▸ | YES1 known ✓ | P07947 | 2/20 | 0.98 |
| ▸ | LYN known ✓ | P07948 | 2/20 | 0.98 |
| ▸ | HCK known ✓ | P08631 | 2/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.98 |
| ▸ | BCR known ✓ | P11274 | 2/20 | 0.98 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 0.98 |
| ▸ | FRK known ✓ | P42685 | 2/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.97 |
| ▸ | FGR known ✓ | P09769 | 1/20 | 0.97 |
| ▸ | BLK known ✓ | P51451 | 1/20 | 0.97 |
| ▸ | SRMS known ✓ | Q9H3Y6 | 1/20 | 0.97 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.98 |
| ▸ | EGFR | P00533 | 2/20 | 0.98 |
| ▸ | CSF1R | P07333 | 2/20 | 0.98 |
| ▸ | RET | P07949 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasatinib Anhydrous SCHEMBL28350326 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29381185 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29482416 | 0.98 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29377489 | 0.98 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL16618598 | 0.98 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL290515 | 0.98 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL1705152 | 0.98 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.98 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28432270 | 0.98 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107260680-B | Dasatinib liposome preparation and preparation method thereof | 上海交通大学 | 2021-02-12 | — | — | CN | claimed |
| US-10023566-B2 | Dasatinib salts | EGIS GYOGYSZERGYAR ZRT (HU) | 2018-07-17 | — | — | US | claimed |
| US-20170183334-A1 | DASATINIB SALTS | EGIS GYOGYSZERGYAR ZRT (HU) | 2017-06-29 | — | — | US | claimed |
| EP-3148991-A1 | DASATINIB SALTS | Egis Gyógyszergyár Zrt. (HU) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181573-A1 | DASATINIB SALTS | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2015-12-03 | — | — | WO | claimed |
| CN-107260680-B | Dasatinib liposome preparation and preparation method thereof | 上海交通大学 | 2021-02-12 | — | — | CN | disclosed |
| CN-111108104-A | Polymorphic forms of dasatinib | 拜康有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10023566-B2 | Dasatinib salts | EGIS GYOGYSZERGYAR ZRT (HU) | 2018-07-17 | — | — | US | disclosed |
| US-10023566-B2 | Dasatinib salts | EGIS GYOGYSZERGYAR ZRT (HU) | 2018-07-17 | — | — | US | disclosed |
| EP-2960341-B1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3263717-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2018-01-03 | — | — | EP | disclosed |
| US-20170315128-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| EP-2492355-B1 | Tissue protective erythropoietin receptor (nepor) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-20140296318-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8357501-B2 | Tissue protective erythropoietin receptor (NEPOR) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| EP-2109690-B9 | EPH-B4 SPECIFIC SIRNA FOR REDUCING EPO-INDUCED TUMOR CELL GROWTH DURING ANEMIA TREATMENT IN CANCER PATIENTS, TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE. | MOLECULAR HEALTH GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245087-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2012-09-27 | — | — | US | disclosed |
| EP-2492355-A1 | Tissue protective erythropoietin receptor (nepor) and methods of use | Life Biosystems GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2109690-B1 | EPH-B4 SPECIFIC SIRNA FOR REDUCING EPO-INDUCED TUMOR CELL GROWTH DURING ANEMIA TREATMENT IN CANCER PATIENTS, TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE. | MOLECULAR HEALTH GMBH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20090306186-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023566-B2 | Dasatinib salts | SRC, PKD1, TP53 | ABL1 8/4885SRC 1/4885LCK 74/4885 |
| US-20170183334-A1 | DASATINIB SALTS | SRC, PKD1, TP53 | ABL1 8/4885SRC 1/4885LCK 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.